Zeniplatin | CAS#111490-36-9

MedKoo Cat#: 341388 | Name: Zeniplatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zeniplatin is a biochemical.

Chemical Structure

Zeniplatin

CAS#111490-36-9

Theoretical Analysis

MedKoo Cat#: 341388

Name: Zeniplatin

CAS#: 111490-36-9

Chemical Formula: C11H18N2O6Pt

Exact Mass: 469.0813

Molecular Weight: 469.36

Elemental Analysis: C, 28.15; H, 3.87; N, 5.97; O, 20.45; Pt, 41.56

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zeniplatin; Zeniplatinum.

IUPAC/Chemical Name

Platinum, (2,2-bis(aminomethyl)-1,3-propanediol-N,N')(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)-

InChi Key

QPWBZVAOCWJTFK-UHFFFAOYSA-L

InChi Code

InChI=1S/C6H8O4.C5H12N2O2.Pt/c7-4(8)6(5(9)10)2-1-3-6;6-1-5(2-7,3-8)4-9;/h1-3H2,(H,7,8)(H,9,10);6-9H,1-4H2;/q;-2;+4/p-2

SMILES Code

C1CC2(C1)C(=O)[O-][Pt+2]3(NCC(CN3)(CO)CO)[O-]C2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 469.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol. 1997;40(5):439-43. PubMed PMID: 9272122. 2: Olver I, Green M, Peters W, Zimet A, Toner G, Bishop J, Ketelbey W, Rastogi R, Birkhofer M. A phase II trial of zeniplatin in metastatic melanoma. Am J Clin Oncol. 1995 Feb;18(1):56-8. PubMed PMID: 7847260. 3: DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al. Pharmacokinetic evaluation of zeniplatin in humans. Cancer Chemother Pharmacol. 1995;36(1):35-40. PubMed PMID: 7720173. 4: Sorensen JB. Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer. 1993 Dec;10(3-4):173-87. Review. PubMed PMID: 8075965. 5: Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T, Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. J Cancer Res Clin Oncol. 1993;119(4):234-6. PubMed PMID: 8423199. 6: Willemse PH, Gietema JA, Mulder NH, de Vries EG, Meijer S, Bouma J, Birkhofer M, Rastogi RB, Sleijfer DT. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer. 1993;29A(3):359-62. PubMed PMID: 8398335. 7: Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992 Dec 15;52(24):6885-9. PubMed PMID: 1458477. 8: Christian MC. The current status of new platinum analogs. Semin Oncol. 1992 Dec;19(6):720-33. Review. PubMed PMID: 1462169. 9: Aamdal S. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs? Ann Oncol. 1992 Nov;3(9):774. PubMed PMID: 1450070. 10: Dodion PF, de Valeriola D, Crespeigne N, Kantrowitz JD, Piccart M, Wery F, Kerger J, Egorin MJ, Forrest A, Bachur NR, et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann Oncol. 1991 Sep;2(8):589-96. PubMed PMID: 1793726. 11: Bitha P, Carvajal SG, Citarella RV, Child RG, Delos Santos EF, Dunne TS, Durr FE, Hlavka JJ, Lang SA Jr, Lindsay HL, et al. Water-soluble third generation antitumor platinum complexes, [2,2-bis (aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato (2-)-O,O']platinum(II) and [1,1-cyclobutanedicarboxylato(2-)-O,O'] [tetrahydro-4H-pyran-4,4-dimethanamine-N,N']platinum(II). J Med Chem. 1989 Aug;32(8):2015-20. PubMed PMID: 2754720. 12: CL 287,110 and CL 286,558. Cancer Invest. 1989;7(5):537. PubMed PMID: 2620257.